Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
All times are local (Market data is delayed by at least 15 minutes).

medigene ag (MDG) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIGENE AG (MDG)

Related News

No related news articles were found.

medigene ag (MDG) Related Businessweek News

No Related Businessweek News Found

medigene ag (MDG) Details

Medigene AG, a biopharmaceutical company, researches and develops drugs to treat cancer and autoimmune diseases in Europe, Asia, and the United States. The company operates in two segments, Marketed Products and Drug Candidates. The Marketed Products segment offers Veregen, an ointment used to treat external genital warts. The Drug Candidates segment’s pipeline products include EndoTAG-1, a drug candidate that has completed two Phase II clinical trials for the treatment of pancreatic and triple-negative breast cancer; and RhuDex, which has completed a pilot Phase IIa clinical trial for the oral treatment of autoimmune diseases. It is also developing dendritic cell vaccines that are in Phase II clinical trials for treating prostate cancer; and Phase I/II clinical trials for the treatment of acute myeloid leukaemia. In addition, this segment develops T cell receptor modified T cells, which is in clinical development stage for the treatment of advanced cancer; T cell-specific monoclonal antibodies that is in pre-clinical trial to treat T cell-induced diseases, such as T cell leukaemia or various autoimmune diseases; and adeno-associated virus-like particles, a technology platform for prophylactic and therapeutic vaccines has completed preclinical study. The company was founded in 1994 and is headquartered in Martinsried, Germany.

62 Employees
Last Reported Date: 05/12/15
Founded in 1994

medigene ag (MDG) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: €527.0K
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €410.0K
Chief Scientific Officer and Member of Execut...
Total Annual Compensation: €285.0K
Compensation as of Fiscal Year 2014.

medigene ag (MDG) Key Developments

MediGene AG Presents at BIO International Convention 2015, Jun-15-2015

MediGene AG Presents at BIO International Convention 2015, Jun-15-2015 . Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States.

MediGene AG Presents at Oddo Seydler Bank Munich Biotech Days, Jul-01-2015

MediGene AG Presents at Oddo Seydler Bank Munich Biotech Days, Jul-01-2015 . Venue: Munich, Germany.

MediGene AG Reports Earnings Results for the First Quarter of 2015; Provides Earnings Guidance for the Year 2015

MediGene AG reported earnings results for the first quarter of 2015. For the quarter, the company’s LBITDA rose to €2,042,000 against €1,452,000 a year ago. The net loss increased to €3,672,000 against €2,044,000 a year ago. The difference to the LBITDA is primarily attributable to foreign exchange losses from non-cash revaluation of €1,531,000. LBITDA rose to €2,042,000 against €1,452,000 a year ago. The net loss increased to €3,672,000 against €2,044,000 a year ago. The difference to the LBITDA is primarily attributable to foreign exchange losses from non-cash revaluation of €1,531,000. Operating loss was €2,254,000 against €1,643,000 a year ago. The company announced that mainly due to these increased investments in Medigene‘s innovations the LBITDA is anticipated to increase to €11 million to 13 million in 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDG:GR €0.00 EUR 0.00

MDG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $307.51 USD +0.60
Hemispherx Biopharma Inc $0.20 USD +0.0031
Merck & Co Inc $57.67 USD +0.07
View Industry Companies
 

Industry Analysis

MDG

Industry Average

Valuation MDG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.4x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIGENE AG, please visit www.medigene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.